321 related articles for article (PubMed ID: 8203853)
1. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Fink MP; Snydman DR; Niederman MS; Leeper KV; Johnson RH; Heard SO; Wunderink RG; Caldwell JW; Schentag JJ; Siami GA
Antimicrob Agents Chemother; 1994 Mar; 38(3):547-57. PubMed ID: 8203853
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
West M; Boulanger BR; Fogarty C; Tennenberg A; Wiesinger B; Oross M; Wu SC; Fowler C; Morgan N; Kahn JB
Clin Ther; 2003 Feb; 25(2):485-506. PubMed ID: 12749509
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin.
Torres A; Bauer TT; León-Gil C; Castillo F; Alvarez-Lerma F; Martínez-Pellús A; Leal-Noval SR; Nadal P; Palomar M; Blanquer J; Ros F
Thorax; 2000 Dec; 55(12):1033-9. PubMed ID: 11083889
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
Ramirez J; Dartois N; Gandjini H; Yan JL; Korth-Bradley J; McGovern PC
Antimicrob Agents Chemother; 2013 Apr; 57(4):1756-62. PubMed ID: 23357775
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin.
Snydman D; Fink M; Niederman M; Reinhart H
Drugs; 1995; 49 Suppl 2():439-41. PubMed ID: 8549393
[No Abstract] [Full Text] [Related]
7. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
Norrby SR; Finch RG; Glauser M
J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
[TBL] [Abstract][Full Text] [Related]
8. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.
Zanetti G; Bally F; Greub G; Garbino J; Kinge T; Lew D; Romand JA; Bille J; Aymon D; Stratchounski L; Krawczyk L; Rubinstein E; Schaller MD; Chiolero R; Glauser MP; Cometta A;
Antimicrob Agents Chemother; 2003 Nov; 47(11):3442-7. PubMed ID: 14576100
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
Caldwell JW; Singh S; Johnson RH
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
[TBL] [Abstract][Full Text] [Related]
10. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.
Solomkin JS; Reinhart HH; Dellinger EP; Bohnen JM; Rotstein OD; Vogel SB; Simms HH; Hill CS; Bjornson HS; Haverstock DC; Coulter HO; Echols RM
Ann Surg; 1996 Mar; 223(3):303-15. PubMed ID: 8604912
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
12. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
Eklund AE; Nord CE
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
[TBL] [Abstract][Full Text] [Related]
13. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Jaccard C; Troillet N; Harbarth S; Zanetti G; Aymon D; Schneider R; Chiolero R; Ricou B; Romand J; Huber O; Ambrosetti P; Praz G; Lew D; Bille J; Glauser MP; Cometta A
Antimicrob Agents Chemother; 1998 Nov; 42(11):2966-72. PubMed ID: 9797234
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Kollef MH; Chastre J; Clavel M; Restrepo MI; Michiels B; Kaniga K; Cirillo I; Kimko H; Redman R
Crit Care; 2012 Nov; 16(6):R218. PubMed ID: 23148736
[TBL] [Abstract][Full Text] [Related]
17. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
Embil JM; Soto NE; Melnick DA
Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
[TBL] [Abstract][Full Text] [Related]
18. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
[TBL] [Abstract][Full Text] [Related]
20. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
